Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleEcallantide.AuthorsZuraw, Bruce; Yasothan, Uma; Kirkpatrick, PeterAbstractIn December 2009, ecallantide (Kalbitor; Dyax) — a recombinant protein inhibitor of plasma kallikrein — was approved by the US FDA for the treatment of acute attacks of hereditary angioedema.SubjectsRECOMBINANT proteins; KALLIKREIN; CHEMICAL inhibitors; ANGIONEUROTIC edema; DRUGSPublicationNature Reviews Drug Discovery, 2010, Vol 9, Issue 3, p189ISSN1474-1776Publication typejournal articleDOI10.1038/nrd3125